Chronic Hepatitis B
Conditions
Interventions
Group A:Diwuyanggan Granules orally taken twice daily for 48 weeks
Entecavir 0.5mg orally taken once daily for 48 weeks.
Group B:Placebo Granules orally taken twice daily for 48 weeks
Entecavir 0.5mg orally taken once daily for 48 weeks
Sponsors
Hubei Provincial Traditional Chinese Medical Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed as HBeAg-negative Chronic Hepatitis B, have not been treated with anti-viral treatment in western medicine in six months; 2. ALT >= 2*ULN or 1*ULN=4, HBVDNA>=1*10^4 copies/ml (Equivalent to 2000 IU/ ml); 3. Patients who have not been treated with Chinese and western medicine to reduce transaminase in the latest month; 4. Male and female aged 18 to 65 years old; 5. To be able to and willing to provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Male and female aged below 18 or above 65 years old; 2. Exclude the same time or overlap with other types of viral hepatitis infection; 3. Confirmed as caused by drug intoxication, alcohol poisoning, hepatitis and autoimmune hepatitis; 4. Patients who have been diagnosed with severe hepatitis, severe hepatitis / liver failure, cirrhosis, liver cancer and have serious primary disease in cardiovascular and cerebrovascular, kidney, lung, endocrine system, hematopoietic system of severe primary disease and patients with mental disease; 5. Pregnant or lactating women; 6. allergic to drug; 7. Patients who have been used interferon antiviral within six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBVDNA;HBV antigen and antibody complete set test;Liver morphological change;Liver Biopsy;Liver Function index;Quality of life scale for Chronic Hepatitis; | — |
Countries
China
Contacts
Public ContactGuoguang Sheng
Outcome results
None listed